Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium – 1997–2006–2016. Part 2

Thomsen HS Marckmann P . Extracellular Gd-CA: Differences in prevalences of NSF. Eur J Radiol 2008; 66: 180–183.

Rydahl C Thomsen HS Marckman P . High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a Gadolinium(Gd)- containing magnetic resonance contrast agent. Invest Radiol 2008; 43: 141–144.

Todd DJ Kagan A Chibnik LB . Cutaneous changes of nephrogenic systemic fibrosis. Predictor of early mortality and association with gadolinium exposure. Arthritis Rheumat 2007; 56: 3433–3441.

Wertman R Altun E Martin DR . Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008; 248: 799–806.

Broome DR . Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008; 66: 230–234.

Pirovano G Munley J Schultz C . Nephrogenic systemic fibrosis: a review of published cases and results from three prospective observational studies. ECR 2012 Book of Abstracts. Insights Imaging 2012; 3(Suppl. 1): S293–S293.

Thomsen HS . ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 2007; 17: 2692–2696.

Thomsen HS Marckmann P Logager VB . Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imag 2007; 7: 130–137.

Kalb RE Helm TN Sperry H . Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol 2008; 8: 607–610.

Daftari Besheli L Aran S Shaqdan K . Current status of nephrogenic systemic fibrosis. Clin Radiol 2014; 69: 661–668.

Thomsen HS Nephrogenic systemic fibrosis and gadolinium-based contrast media. In: Thomsen HS Webb JAW (eds). Contrast Media: Safety Issues and ESUR Guidelines, 3rd ed. Heidelberg: Springer, 2014, pp. 201–217.

Wollanka H Weidenmaier W Giersig C . NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transplant 2009; 24: 3882–3884.

Elmholdt TR Jørgensen B Ramsing M . Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT Plus 2010; 3: 285–287.

Collidge T Thomson P Mark P . Is this really a true case of NSF following Gadovist exposure alone? Nephrol Dial Transplant 2010; 24: 1352–1353.

Reilly PF . Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008; 3: 747–751.

Amet S Launay-Vacher V Clément O . Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents. The Prospective Fibrose Nephrogénique Systémique Study. Invest Radiol 2013; 49: 109–115.

Bennett CL Qureshi ZP Sartor AOS . Gadolinium induced nephrogenic systemic fibrosis, the rise and fall of an iatrogenic disease. Clin Kidney J 2012; 5: 82–88.

Thomsen HS . NSF: Still relevant. J Magn Reson Imaging 2014; 40: 11–12.

ESUR Contrast Media Safety Committee. ESUR Guidelines on Contrast Media 9.0. 2014. ESUR Office Vienna.

Abraham JL Thakral C Skov L . Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008; 158: 273–280.

High WA Ayers RA Chandler J . Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 27–30.

White GW Gibby WA Tweedle MF . Comparison of Gd (DTPA-BMA) (Omniscan) versus GD (HP-DO3A) (Prohance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006; 41: 272–278.

Abraham JL Thakral C . Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol 2008; 66: 200–207.

Marckmann P Skov L Rossen K . Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; 22: 3174–3178.

Van der Molen AJ Diagnostic efficacy of gadolinium-based contrast media. In: Thomsen HS Webb JAW (eds). Contrast Media: Safety Issues and ESUR Guidelines, 3rd ed. Heidelberg: Springer, 2014, pp. 181–191.

Kanal E Barkovich AJ Bell C . ACR guidance document for safe MR practices: 2007. Am J Roentgenol 2007; 188: 1447–1474.

Thomsen HS Marckmann P Logager VB . Enhanced computed tomography or magnetic resonance imaging: A choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Acta Radiol 2007; 48: 593–596.

Diego DR . Nephrogenic system fibrosis: a radiologist’s practical perspective. Eur J Radiol 2008; 66: 220–224.

Morcos SK Thomsen HS Webb JAW . Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR) Dialysis and contrast media. Eur Radiol 2002; 12: 3026–3030.

Thomsen HS . Contrast enhanced MRI in patients with impaired renal function: recent recommendations to minimize the risk of nephrogenic systemic fibrosis. Solutions in Contrast Imaging 2010; 1: 1–8.

Thomsen HS . Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol 2006; 16: 2619–2621.